Ligand Pharma (LGND) Tops Q2 EPS by 17c ; Offers Guidance

Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.60, $0.17 better than the analyst estimate of $1.43. Revenue for the quarter came in at $47.63 million versus the consensus estimate of $43.74 million.

GUIDANCE:

Ligand Pharma sees FY2025 EPS of $6.70-$7.00, versus the consensus of $6.12. Ligand Pharma sees FY2025 revenue of $200-225 million, versus the consensus of $194 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Vail Resorts (MTN) 2200 contracts October 145 puts trade into quarter results
• Active options: NVDA TSLA AAPL INTC META MU AMD AMZN MSFT SPCX
• William Blair Downgrades Lifecore Biomedical (LFCR) to Market Perform